The once-daily human GLP-1 analogue liraglutide decreases postprandial hunger and energy intake

被引：0
|
作者：
Flint, Anne
Kapitza, Christoph
Hinds-Berger, Charlotte
Zdravkovic, Milan
机构：
来源：
DIABETES | 2008年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A165 / A165
页数：1
相关论文
共 50 条
  • [21] Patient reported outcomes in subjects with type 2 diabetes treated with monotherapy regimens of once-daily human GLP-1 analogue liraglutide or glimepiride
    Bode, B. W.
    Hale, P. M.
    Hammer, M.
    Testa, M. A.
    Garber, A.
    DIABETOLOGIA, 2008, 51 : S357 - S358
  • [22] The once-daily human GLP-1 analogue liraglutide increases the beta cell mass in normoglycaemic mice by directly accelerating cell differentiation and proliferation
    Shimoda, M.
    DIABETOLOGIA, 2009, 52 : S34 - S35
  • [23] The Pharmacokinetics, Pharmacodynamics, and Tolerability of Liraglutide, a Once-Daily Human GLP-1 Analogue, After Multiple Subcutaneous Administration in Healthy Chinese Male Subjects
    Jiang, Ji
    Zhang, Jianyan
    Jacobsen, Lisbeth V.
    Hu, Pei
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (12): : 1620 - 1627
  • [24] Pharmacokinetic modelling of the once-daily human GLP-1 analogue liragiutide in healthy volunteers and comparison to exenatide
    Jonker, Daniel
    Toft, Anders D.
    Kristensen, Peter
    Knudsen, Lotte
    Watson, Estelle
    DIABETES, 2007, 56 : A160 - A160
  • [25] Greater glycaemic control is achieved with the once-daily human GLP-1 analogue liraglutide vs comparators across the continuum of estimated beta cell mass
    Meier, J. J.
    Vilsboll, T.
    Donsmark, M.
    Hartvig, H.
    Nauck, M. A.
    DIABETOLOGIA, 2011, 54 : S322 - S322
  • [26] Liraglutide, the once-daily human GLP-1 analogue, has a protracted profile based on both delayed absoprtion and a long plasma half-life
    Knudsen, L. Bjerre
    Nielsen, P. F.
    Steensgaard, D. B.
    Bloch, P.
    Lau, J.
    Agersoe, H.
    DIABETOLOGIA, 2009, 52 : S305 - S306
  • [27] Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide
    Horowitz, M.
    Vilsboll, T.
    Zdravkovic, M.
    Hammer, M.
    Madsbad, S.
    DIABETES OBESITY & METABOLISM, 2008, 10 (07): : 593 - U4
  • [28] Metabolism and excretion of the once-daily human GLP-1 analogue liraglutide in healthy subject and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase
    Bjornsdottir, I.
    Olsen, A.
    Larsen, U.
    Helleberg, H.
    Vanggaard, J.
    Oosterhuis, B.
    van Lier, J.
    Zdravkovic, M.
    Malm-Erjefalt, M.
    DIABETOLOGIA, 2008, 51 : S356 - S356
  • [29] Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
    Astrup, A.
    Carraro, R.
    Finer, N.
    Harper, A.
    Kunesova, M.
    Lean, M. E. J.
    Niskanen, L.
    Rasmussen, M. F.
    Rissanen, A.
    Rossner, S.
    Savolainen, M. J.
    Van Gaal, L.
    INTERNATIONAL JOURNAL OF OBESITY, 2012, 36 (06) : 843 - 854
  • [30] Liraglutide, a once-daily human GLP-1 analog, significantly improves β-cell function in subjects with type 2 diabetes
    Matthews, David
    Marre, Michel
    Le-Thl, T. U. Duyen
    Zdravkovic, Milan
    Simo, Rafael
    DIABETES, 2008, 57 : A150 - A151
12345